ACADIA Pharmaceuticals Inc (ACAD)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 91.46% | 91.61% | 91.72% | 92.27% | 94.27% | 95.86% | 97.52% | 98.29% | 98.03% | 97.98% | 97.10% | 96.47% | 96.05% | 95.39% | 95.68% | 95.58% | 95.35% | 95.09% | 94.79% | 94.54% |
| Operating profit margin | 24.10% | 12.08% | 2.56% | -0.56% | -10.10% | -24.43% | -23.14% | -31.56% | -43.23% | -43.44% | -40.32% | -43.95% | -35.20% | -40.67% | -56.88% | -57.58% | -64.87% | -65.82% | -59.87% | -67.84% |
| Pretax margin | 26.94% | 14.71% | 5.14% | 1.83% | -7.03% | -20.83% | -19.22% | -28.03% | -41.27% | -42.12% | -39.78% | -43.33% | -34.60% | -40.25% | -56.33% | -56.60% | -63.60% | -63.78% | -57.15% | -64.85% |
| Net profit margin | 23.64% | 13.83% | 3.43% | -0.21% | -8.44% | -23.55% | -20.12% | -28.05% | -41.76% | -42.49% | -39.93% | -43.50% | -34.67% | -40.37% | -56.49% | -56.74% | -63.74% | -63.92% | -57.29% | -64.99% |
ACADIA Pharmaceuticals Inc's profitability ratios have shown a mixed performance over the reported periods.
1. Gross profit margin has generally trended upwards over time, reaching its peak at 98.29% as of March 31, 2023. This indicates that the company has been able to improve its efficiency in generating profits from its sales.
2. Operating profit margin, after facing a series of negative values, has shown a significant improvement in recent periods. The margin turned positive as of December 31, 2023, and has been increasing steadily since then, reaching 24.10% by the end of December 31, 2024. This suggests that the company has been able to control its operating expenses more effectively.
3. Pretax margin has followed a similar pattern to the operating profit margin. Starting from negative values, it has turned positive as of March 31, 2024. The pretax margin has been increasing consistently, indicating that the company's pre-tax profitability has been improving.
4. Net profit margin, like the previous ratios, has shown a positive trend, turning positive by March 31, 2024. The net profit margin has been increasing steadily, reaching 23.64% by December 31, 2024, highlighting an improvement in the company's overall profitability and efficiency in managing its costs.
Overall, ACADIA Pharmaceuticals Inc has demonstrated an upward trend in its profitability ratios, reflecting improvements in operational efficiency and cost management. However, fluctuations in these ratios over different periods suggest the need for continued monitoring and strategic adjustments to sustain and enhance profitability in the future.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 19.43% | 11.49% | 2.50% | -0.54% | -9.80% | -24.41% | -19.83% | -25.05% | -38.04% | -36.88% | -33.72% | -34.71% | -24.34% | -26.88% | -36.38% | -34.94% | -36.62% | -34.67% | -30.98% | -33.24% |
| Return on assets (ROA) | 19.07% | 13.15% | 3.34% | -0.20% | -8.18% | -23.53% | -17.24% | -22.27% | -36.74% | -36.07% | -33.39% | -34.36% | -23.98% | -26.69% | -36.13% | -34.43% | -35.98% | -33.66% | -29.64% | -31.84% |
| Return on total capital | 7.18% | 13.96% | 4.41% | -1.00% | -17.00% | -42.64% | -32.21% | -43.86% | -55.84% | -52.20% | -47.52% | -48.72% | -31.51% | -33.89% | -46.51% | -45.22% | -45.58% | -42.12% | -35.50% | -38.91% |
| Return on equity (ROE) | 30.90% | 22.26% | 5.92% | -0.37% | -14.19% | -41.09% | -28.00% | -38.99% | -53.94% | -51.06% | -47.06% | -48.22% | -31.04% | -33.78% | -46.34% | -44.71% | -44.91% | -40.90% | -33.96% | -37.28% |
ACADIA Pharmaceuticals Inc's profitability ratios have shown a notable improvement over the last few quarters. The Operating return on assets (Operating ROA), which measures the efficiency of generating operating profits from its assets, has gradually increased from negative percentages in March 2023 to positive percentages by December 2024. This indicates that the company has been more effective in generating profits from its core operations.
Similarly, the Return on assets (ROA), which provides a broader picture of the company's overall efficiency in generating profits from all its assets, has also shown a positive trend, moving from negative percentages to positive percentages over the same period. This reflects an improvement in the company's overall profitability and asset utilization.
Furthermore, the Return on total capital, which assesses the company's profitability in relation to its total capital invested, has also seen a steady increase from negative percentages to positive percentages by December 2024. This suggests that ACADIA Pharmaceuticals Inc has been able to generate better returns for its total capital base.
Lastly, the Return on equity (ROE), which measures the company's ability to generate profits from its shareholders' equity, has exhibited significant growth, turning from negative percentages to strong positive percentages by December 2024. This indicates that the company has been more efficient in generating returns for its equity investors.
Overall, the improving profitability ratios of ACADIA Pharmaceuticals Inc demonstrate a positive trend in the company's financial performance and efficiency in utilizing its assets and capital to generate profits for its stakeholders.